

## Lung cancer: When radiotherapy fails

July 5 2022, by Robert Emmerich



On the left, a stained adenocarcinoma from the lung. The enlarged section B shows healthy lung tissue, the enlarged section C an adenocarcinoma. Section D shows the PET-CT of a metabolically active central lung tumor, close to the trachea, heart and esophagus. The irradiation dose distribution is shown in color: Desired dose 100% in the tumor and 80% in the extended tumor area. 25% and 10% of the irradiation dose (turquoise and blue lines) in the healthy tissue for technical reasons. Credit: Oliver Hartmann, JMU / Thomas Fischer, UKW

Lung cancer is the most common cancer in the world, with 2.2 million new cases and around 1.8 million deaths in 2020 alone. Although knowledge about the disease has improved considerably, and new therapeutic strategies can prolong the lives of previously incurable patients, the numbers clearly show that lung cancer is still a serious



disease and the mortality rate is still far too high.

To further reduce the number of deaths from this type of tumor, novel and improved treatments are needed. Würzburg researchers are concentrating on radiotherapy. In combination with chemotherapy, this is still one of the most important treatment approaches. This is especially true for late-stage non-small cell lung tumors, where <u>treatment options</u> are rather limited.

## PTEN mutation is suitable as a biomarker

In this type of lung tumor, radiotherapy can be ineffective. This is due to the interaction of a common, specific mutation in the PTEN gene with the DNA repair enzyme ATM, as the Würzburg team found out.

However, lung tumors, in which this mutation occurs, can be therapeutically influenced. With two experimental inhibitors, the researchers succeeded in blocking the DNA repair enzyme in the tumor cells. As a result, the tumors became sensitive to radiation again and could be killed in tumor models.

## **Inhibitors in preclinical testing**

"Such inhibitors have not yet been approved for use in humans, but partake in clinical trials," explains cancer researcher Dr. Markus Diefenbacher from the Biocentre at the University of Würzburg. His team has published the new findings in the journal *Cell & Bioscience* together with a group led by radiotherapist Dr. Thomas Fischer from Professor Michael Flentje's research group at the University Hospital Würzburg.

If the inhibitors pass the clinical tests, they offer a new opportunity: the



PTEN mutation is suitable as a biomarker that indicates a tumor's resistance to radiation. With corresponding analyses, one could specifically identify patients who might benefit from a combination of inhibitor and radiotherapy. This could be realized quickly: patients with non-small cell <u>lung cancer</u> are already routinely examined for PTEN and other disease-relevant mutations.

## Focus on radiation dose reduction

Currently, several <u>clinical trials</u> are looking at the impact of PTEN and ATM on treatment outcomes. "We are confident that our new findings will generate a lot of interest in pursuing this innovative strategy for the treatment of non-small cell lung tumors," says Professor Michael Flentje.

Radiotherapy is a mainstay in the treatment of late-stage tumors of the respiratory tract and other organs. The Würzburg team is therefore continuing to research new strategies and targets. One focus is on reducing the <u>radiation dose</u> in such a way that the desired therapeutic success is still achieved and at the same time the healthy tissue around the tumor is spared as much as possible.

**More information:** Thomas Fischer et al, PTEN mutant non-small cell lung cancer require ATM to suppress pro-apoptotic signalling and evade radiotherapy, *Cell & Bioscience* (2022). DOI: 10.1186/s13578-022-00778-7

Provided by Julius-Maximilians-Universität Würzburg

Citation: Lung cancer: When radiotherapy fails (2022, July 5) retrieved 12 May 2024 from <u>https://medicalxpress.com/news/2022-07-lung-cancer-radiotherapy.html</u>



This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.